OneMedNet shares surge 30.28% after-hours on 815% Q3 bookings growth and Palantir partnership.

OneMedNet surged 30.28% in after-hours trading following a series of bullish developments. The stock’s rally was driven by new FDA clearances, a 815% quarterly bookings increase attributed to strategic partnerships—including Palantir Foundry—and a 22% expansion of its iRWD™ network to 2,130 provider sites. Additionally, the launch of an AI-powered data exploration feature and a live RWD subscription feed reinforced investor confidence in its real-world data capabilities. Institutional buying, including a significant share purchase by director Thomas Kosasa, further signaled support for the company’s AI-driven healthcare data strategy. These advancements, combined with operational momentum in clinical exams and patient records, positioned OneMedNet as a high-growth player in the AI-integrated healthcare technology sector, fueling the after-hours price spike.